After having been notified that CHMP was likely to issue a negative opinion regarding its MAA for Linhaliq dual release inhaled ciprofloxacin for the treatment of P. aeruginosa lung infections in patients with non-cystic fibrosis bronchiectasis (NCFBE), Aradigm has withdrawn the application. The company initially submitted the MAA in March 2018.
Aradigm filed for bankruptcy in February 2019. According to the announcement, bids for the company’s assets, including its intellectual property, are expected within the next 30-60 days.
Read the Aradigm press release.
